Trial Profile
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-‑Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2025
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Selinexor (Primary)
- Indications Multiple myeloma; Plasmacytoma
- Focus Registrational; Therapeutic Use
- Acronyms STORM
- Sponsors Karyopharm Therapeutics
- 05 Mar 2025 According to an Antengene Corporation media release, company announced that the Indonesia National Agency of Drug and Food Control has approved a New Drug Application for XPOVIO (selinexor) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory MM who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD3 monoclonal antibody.
- 06 Dec 2023 According to an Antengene Corporation media release, the Pharmaceutical Administration Bureau of Macau has approved a NDA for XPOVIO (selinexor), applicable in combination with dexamethasone (Xd), for the treatment of adult patients with relapsed and/or refractory multiple myeloma (R/R MM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors (PIs), two immunomodulatory agents (IMiDs), an anti-CD38 monoclonal antibody.
- 26 Sep 2023 According to a Karyopharm Therapeutics media release, data from this trial will be presented at the 2023 International Myeloma Society (IMS) Annual Meeting, being held September 27-30 in Athens, Greece.